Skip to main content
. 2022 Oct 23;15:150. doi: 10.1186/s13045-022-01374-5

Table 4.

Non-hematologic adverse events

Any, n (%) Grade ≥ 3, n (%)
Daratumumab IRR
 Cycle 1 (N = 31) 15 (48.4) 3 (9.7)
 Cycle 2 (N = 29) 1 (3.4) 0
 Cycle 3 (N = 25) 0 0
 During DARA consolidation 0 0
Nausea 7 (22.6) 1 (3.2)
Dyspepsia 4 (12.9) 0
Diarrhea 4 (12.9) 0
Stomatitis 4 (12.9) 0
Constipation 3 (9.7) 0
Hypertension 3 (9.7) 1 (3.2)
Anorexia 2 (6.5) 0
Peripheral sensory neuropathy 2 (6.5) 0
Hyperglycemia 1 (3.2) 1 (3.2)
Treatment related death 1 (3.1) NA

IRR infusion-related reaction; NA not applicable